Gaudium IVF and Women Health Share Price Target 2026, 2027, 2030, 2040, 2050
Gaudium IVF and Women Health is a famous Indian healthcare company. The company focuses on fertility treatments and women’s health and has grown into a large network with 7 main centres and 28 smaller centres across India. It offers services like IVF, IUI, ICSI, egg and embryo freezing, help for couples with difficult fertility problems, treatment for PCOS/PCOD and endometriosis, care for high-risk pregnancies, painless labour, minor surgeries, and advanced tests like genetic screening. It is known as India’s first “Radiation-Free” IVF centre and its GAAT system, which uses genetic information to give better treatment.
What is Gaudium IVF and Women Health Ltd?
Gaudium IVF and Women Health is a fertility and women’s health care company started in 2015 in New Delhi, India, by Dr Manika Khanna, a specialist in helping couples have babies. The company has more than 30 centres across India and offers treatments like IVF, ICSI, IUI, and help for male fertility problems. They also provide services like egg and embryo freezing, care for high-risk pregnancies, minor surgeries, and general women’s health support. It helps families have children and supports women’s health in a safe and easy way using modern equipment and a kind, patient-friendly approach.
It began as a single clinic but has now grown into a large network of centres in many states. This growth is due to the company’s focus on quality care, patient satisfaction, and high success rates. Over time, the company has built a strong reputation for trust, reliability, and expertise in fertility care. It uses modern medical methods and has special programs to handle complex fertility problems, making it one of the most respected names in reproductive health in India. In 2026, its share price target would be ₹181, as per stock market analysts.
According to stock market analysts, its share price would be between ₹61 to ₹181 in 2026.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2026 | 61 | 181 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | — | — |
| February | 68 | 98 |
| March | 65 | 124 |
| April | 61 | 144 |
| May | 70 | 157 |
| June | 77 | 163 |
| July | 85 | 168 |
| August | 90 | 171 |
| September | 99 | 174 |
| October | 110 | 176 |
| November | 125 | 178 |
| December | 130 | 181 |
The main mission is to help couples enjoy the joy of becoming parents while also looking after women’s health. The clinic understands the emotional, mental, and physical needs of patients along with their medical needs. This approach helps reduce stress during fertility treatments and makes couples feel supported throughout the process. The company treats every patient like family, giving guidance, reassurance, and clear information about fertility options so they can make informed choices. In 2027, its share price target would be ₹300, as per stock market analysts.
According to stock market analysts, its share price would be between ₹168 to ₹300 in 2027.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2027 | 168 | 300 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 168 | 200 |
| February | 171 | 218 |
| March | 177 | 229 |
| April | 180 | 237 |
| May | 184 | 245 |
| June | 189 | 256 |
| July | 198 | 266 |
| August | 211 | 275 |
| September | 223 | 281 |
| October | 235 | 284 |
| November | 249 | 289 |
| December | 258 | 300 |
It has grown to a network of more than 30 centres across India using a hub-and-spoke model. The main hubs have advanced medical and laboratory facilities, while smaller centres make it easier for local patients to get treatment. Its main centres include Delhi, Mumbai, Bengaluru, Patna, Ludhiana, and Srinagar. This wide presence allows patients to access fertility care without travelling far. It also helps couples from rural and semi-urban areas get high-quality reproductive health services with the same medical standards in every centre. In 2028, its share price target would be ₹435, as per stock market analysts.
According to stock market analysts, its share price would be between ₹290 to ₹435 in 2028.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2028 | 290 | 435 |
It offers many types of fertility treatments to meet different patient needs. These include Intrauterine Insemination (IUI) to help sperm meet the egg, Intracytoplasmic Sperm Injection (ICSI) for male infertility, and ovulation induction for hormonal problems. The clinic also performs tests to find the main cause of infertility and provides surgeries if needed. Couples who had failed attempts before are given special care to improve their chances of pregnancy while keeping treatments safe and comfortable. In 2029, its share price target would be ₹560, as per stock market analysts.
According to stock market analysts, its share price would be between ₹411 to ₹560 in 2029.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2029 | 411 | 560 |
It also provides care for women who have health problems that can affect fertility. Treatments are available for conditions like Polycystic Ovary Syndrome (PCOS), endometriosis, blocked fallopian tubes, and irregular ovulation. The clinic performs laparoscopic and hysteroscopic surgeries when needed. Besides fertility treatments, the clinic offers general women’s health services, prenatal care, and guidance for high-risk pregnancies, giving women complete support for their reproductive health. In 2030, its share price target would be ₹722, as per stock market analysts.
According to stock market analysts, its share price would be between ₹545 to ₹722 in 2030.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2030 | 545 | 722 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 545 | 602 |
| February | 559 | 621 |
| March | 562 | 638 |
| April | 570 | 644 |
| May | 574 | 658 |
| June | 578 | 667 |
| July | 562 | 675 |
| August | 567 | 681 |
| September | 572 | 685 |
| October | 590 | 690 |
| November | 622 | 710 |
| December | 638 | 722 |
It knows that infertility can affect men too, so it provides special care for male patients. Services include sperm analysis, hormone testing, and surgical sperm retrieval for men with low sperm count, poor movement, or blockages. The clinic makes sure both partners get a full assessment and care. Male fertility treatments are given with sensitivity and support, helping patients feel comfortable during tests and procedures. This approach increases the chances of conception and makes fertility treatments more effective for couples. In 2040, its share price target would be ₹1745, as per stock market analysts.
According to stock market analysts, its share price would be between ₹1441 to ₹1745 in 2040.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2040 | 1441 | 1745 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 1441 | 1521 |
| February | 1462 | 1550 |
| March | 1475 | 1574 |
| April | 1489 | 1590 |
| May | 1510 | 1611 |
| June | 1525 | 1630 |
| July | 1533 | 1651 |
| August | 1554 | 1668 |
| September | 1568 | 1686 |
| October | 1584 | 1711 |
| November | 1622 | 1732 |
| December | 1640 | 1745 |
It also offers egg, embryo, and sperm freezing to preserve fertility for the future. Cryopreservation allows patients to save healthy eggs or embryos to use later, avoiding repeated ovarian stimulation. This is helpful for people who want to delay having children or those going through medical treatments like chemotherapy that may affect fertility. The clinic follows strict safety measures to make sure frozen eggs, embryos, or sperm stay safe and usable in the future. In 2050, its share price target would be ₹4077, as per stock market analysts.
According to stock market analysts, its share price would be between ₹3740 to ₹4077 in 2050.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2050 | 3740 | 4077 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 3740 | 3855 |
| February | 3775 | 3874 |
| March | 3790 | 3898 |
| April | 3800 | 3922 |
| May | 3815 | 3952 |
| June | 3832 | 3968 |
| July | 3850 | 3984 |
| August | 3878 | 3998 |
| September | 3900 | 4011 |
| October | 3933 | 4032 |
| November | 3945 | 4051 |
| December | 3958 | 4077 |
Should I buy Gaudium IVF and Women Health stock?
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2026 | 61 | 181 |
| 2027 | 168 | 300 |
| 2028 | 290 | 435 |
| 2029 | 411 | 560 |
| 2030 | 545 | 722 |
| 2040 | 1441 | 1745 |
| 2050 | 3740 | 4077 |
It could be a good choice for people who want to invest for the long term and believe that healthcare and fertility services in India will grow. The company has shown good growth in sales and profits, and works in a special area with rising demand. But there are some risks too, like depending on patients coming in, needing skilled staff, following rules, and having most income from a single business. Its performance could be affected by fewer patients, a slow economy, or a bad reputation. So, it is better for investors who can handle these risks, while cautious investors may want to wait.
Gaudium IVF and Women Health earnings results (Financials)
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
| Sales + | 37 | 44 | 48 | 71 |
| Expenses + | 23 | 24 | 28 | 42 |
| Operating Profit | 14 | 20 | 19 | 29 |
| OPM % | 37% | 46% | 41% | 41% |
| Other Income + | 0 | 0 | 0 | 0 |
| Interest | 1 | 0 | 1 | 2 |
| Depreciation | 1 | 1 | 2 | 2 |
| Profit before tax | 12 | 18 | 17 | 25 |
| Tax % | 26% | 26% | 38% | 25% |
| Net Profit + | 9 | 14 | 10 | 19 |
| EPS in Rs | 89.17 | 136.54 | 104.22 | 3.12 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
Is Gaudium IVF and Women Health stock good to buy? (bull case & bear case)
Bull Case:
- In FY25, the company made a net profit of around ₹13–19 crore.
- The company’s total revenue in FY25 was about ₹70 crore. This shows the business is expanding and getting more patients every year.
- It runs over 30 centres across India using a hub-and-spoke model, making fertility care accessible to more people.
- ROE and ROCE are strong at over 39 %, which shows the company uses its money efficiently to earn profits.
- The company has plans to expand into new cities and open more IVF centres, which can increase patients and revenue.
- Modern labs and advanced technology improve IVF success rates and attract more patients.
Bear Case:
- Most of the company’s income comes from IVF and fertility treatments, so if patient numbers drop, profits can go down.
- ROE and ROCE have shown slight moderation in some periods, hinting at possible cost pressures.
- IVF treatments are mostly paid out-of-pocket, so economic slowdowns may reduce demand.
- Expansion and technology upgrades require investment, which may strain finances if not managed well.
Conclusion
It is a growing healthcare company in India that focuses on fertility treatments and women’s health. It has a network of more than 30 centres across the country. The company has been making steady profits and growing its revenue, and it uses modern technology and advanced labs to improve IVF success rates. It keeps expanding its centres, manages its loans well, and runs the business carefully. Overall, it can be a good long-term investment for people who can handle these risks.
